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Background: Animal studies suggest a role of inﬂammation in the pathophysiology of anxiety, but human
studies of inﬂammatory markers and anxiety disorders are scarce. We report a study of serum C-reactive
protein (CRP) and generalised anxiety disorder (GAD) from the general population-based ALSPAC birth
cohort.
Methods: DSM-IV diagnosis of GAD was obtained from 5365 cohort members during face-to-face clinical
assessment at age 16 years, of which 3392 also provided data on serum high sensitivity CRP levels.
Logistic regression calculated odds ratio (OR) for GAD among individuals in top and middle thirds of CRP
distribution compared with the bottom third. Effect of comorbid depression was assessed. Age, sex, body
mass, ethnicity, social class, maternal education, maternal age at delivery, and family history of in-
ﬂammatory conditions were included as potential confounders.
Results: Forty participants met DSM-IV criteria for GAD (0.74%). CRP levels were higher in GAD cases
compared with the rest of the cohort (P ¼ 0.005). After adjusting for potential confounders, participants
in the top third of CRP values compared with the bottom third were more likely to have GAD; adjusted
OR 5.06 (95% CI, 1.31e19.59). The association between CRP and GAD was consistent with a linear dose-
response relationship. The pattern of association between CRP and GAD remained unchanged after
excluding cases with co-morbid depression.
Conclusions: The ﬁndings are consistent with a role of inﬂammation in anxiety disorders. Longitudinal
studies of inﬂammatory markers, subsequent anxiety taking into account current and past psychological
stress are required to understand this association further.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Emerging evidence indicates an important role of inﬂammationneralized anxiety disorder;
ren; DSM-IV, diagnostic and
ICV, intra-cerebroventricular;
and Well-being Assessment;
, odds ratio; CI, conﬁdence
atry, Box 189, Cambridge
Khandaker).
Inc. This is an open access article uin the pathophysiology of mood and anxiety disorders where in-
ﬂammatory cytokines are thought to play a key role (Khandaker
et al., 2014; Dantzer et al., 2008; Hodes et al., 2014). In healthy
volunteers, simulated bacterial infection with the injection of an
immune activating agent, lipopolysaccharide (LPS, a bacterial cell
wall endotoxin), has been reported to produce anxiety and low
mood as well as increased serum levels of interleukin 6 (IL-6, an
inﬂammatory cytokine) (Reichenberg et al., 2001). Similarly, in
mice immune activation is associated with anxiety-like behaviour
as well as increased proinﬂammatory cytokines both in peripheral
circulation and the brain (Gibney et al., 2013; Rossi et al., 2012).
Moreover, anxiety inducing effects of social stress could be blocked
by intra-cerebroventricular (ICV) administration of IL-1b (ander the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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stress exposure (Rossi et al., 2012). The results indicate inﬂamma-
tory cytokines are important mediators of the relationship between
psychological stress and anxiety in the central nervous system
(CNS). However, despite these intriguing ﬁndings from preclinical
research human studies of inﬂammation and anxiety are scarce.
Rarer still are general population-based studies that are less prone
to bias arising from inappropriate control selection. Existing studies
are limited in number and have mixed ﬁndings; some suggest an
association between anxiety symptoms and circulating inﬂamma-
tory markers, such as C-reactive protein (CRP) (Liukkonen et al.,
2011; Pitsavos et al., 2006), while others do not (Copeland et al.,
2012; Baune et al., 2012). Methodological issues, such as study
design, physical comorbidity, methods for measuring CRP and
anxiety, might account for some of the discrepancy in ﬁndings in
existing studies (see discussion). A clearer understanding of the
association between anxiety and inﬂammation would come from
studies that are based on general population samples, include
robust assessment of inﬂammation, anxiety disorder as well as
relevant socio-demographic, physical and clinical parameters, thus
reducing chances of bias and confounding.
Using data from the general population-based Avon Longitudi-
nal Study of Parents and Children (ALSPAC) birth cohort, we report
a study of generalised anxiety disorder (GAD), diagnosed according
Diagnostic and Statistical Manual of Mental Disorders fourth edi-
tion (DSM-IV) criteria, and serum CRP levels in adolescence at age
16 years. We have used a clinical diagnosis of GAD as the outcome
rather than all anxiety disorders or anxiety symptoms, because
anxiety disorders include a range of conditions with varied pre-
sentations that might have different pathophysiology and aeti-
ology, whilst anxiety symptoms are non-speciﬁc and may
accompany many physical and mental illnesses.
2. Methods and materials
2.1. Sample
The ALSPAC birth cohort comprises 14,062 live births from
pregnant women resident in county Avon, a geographically deﬁned
region in southwest of England, with expected dates of delivery
between April 1991 and December 1992 (http://www.bristol.ac.uk/
alspac/) (Boyd et al., 2013; Fraser et al., 2013). Avon included both
urban and rural areas, and the population was broadly represen-
tative of all children in the UK. The parents completed regular
postal questionnaires about all aspects of their child's health and
development since birth. Since the age of 7 years the entire cohort
attended an annual assessment clinic during which they partici-
pated in a range of face-to-face interviews and physical tests.
The current study is based on 5365 cohort members who took
part in psychiatric assessment at age 16 years, of which 3392 also
provided data on serum CRP levels. Analysis of the association
between CRP and GAD was based on this sample of 3392. We
subsequently repeated the analysis after imputation of missing CRP
data (N ¼ 5365).
Ethical approval for the study was obtained from ALSPAC Ethics
and Law Committee and the Local Research Ethics Committees.
2.2. Assessment of GAD
Diagnosis of GAD according to DSM-IV criteria was obtained
using computerised child version of the Development and Well-
being Assessment (DAWBA), which was administered on 5365
cohort members during face-to-face clinical assessment at age 16
years (Goodman et al., 2000; APA, 1995). DAWBA assessed symp-
toms of GAD occurring in the six-month period preceding theassessment. In addition, it included questions on symptom severity,
duration, and their effect on life and development. All individuals
with no psychiatric diagnosis or a diagnosis other than GAD were
included in the comparison group.
2.3. Measurement of CRP
Blood samples were collected from participants who gave con-
sent for venepuncture during clinical assessment at age 16 years.
Participants fasted overnight before attending the clinic if seen in
the morning, or at least for 6 h if seen in the afternoon. Blood
samples were immediately spun, frozen and stored at 80 C,
which were analysed within 3e9 months of blood sampling with
no freeze-thaw cycles in between. High sensitivity CRP was
measured by automated particle-enhanced immunoturbidimetric
assay (Roche UK, Welwyn Garden City, UK). A valid measure of
serum CRP was obtained from 3490 participants in total, which
ranged from0.07 to 72.55mg/L (60 subjects over 10mg/L). No other
inﬂammatory makers were measured.
The sample was divided into three groups based on the tertiles
of CRP distribution in all 3490 subjects regardless of their case or
non-case status at follow-up. Values for the 33rd and 66th per-
centiles of the CRP distribution were 0.26 mg/L and 0.64 mg/L
respectively. Thus, CRP levels for participants in the bottom, middle
and top thirds of the distribution were 0.07e0.25 mg/L,
0.26e0.63 mg/L, and 0.64e72.55 mg/L respectively.
2.4. Assessment of potential confounders
We included a number of socio-demographic, physical and
clinical parameters that are relevant to CRP levels and psychiatric
illnesses. The data were collected during face-to-face clinical as-
sessments or by postal questionnaires completed by parents. We
included age at the time of assessment of GAD (inweeks), sex, body
mass index (BMI) at the time of assessment of CRP, ethnicity, fa-
ther's social class, maternal age at delivery and educational level. As
per the UKOfﬁce of National Statistics classiﬁcation system, father's
social class was recorded in six categories: I, II, III non-manual, III
manual, IV, V (in descending order with professionals and higher
managerial workers representing social class I). Maternal age at
delivery was grouped into six categories (age in years: <20, 20e24,
25e29, 30e34, 35e40, >40). Maternal highest educational
achievement was recorded in four groups (secondary school,
vocational qualiﬁcation, O level, A level, degree). In addition, we
included family history of chronic inﬂammatory conditions:
arthritis and rheumatism in mothers and maternal grandparents.
Finally, we examined the effect of concurrent infection, and sepa-
rately, depression (assessed by DAWBA) on the association between
GAD and CRP (see below). We did not include the use of anti-
inﬂammatory or psychotropic medications as potential con-
founders as the numbers of adolescent subjects taking these drugs
are likely to be small.
2.5. Statistical analysis
2.5.1. Baseline comparison
Baseline characteristics between cases of GAD and the rest of the
cohort were compared using the Chi-square test and independent
sample t-test for categorical and continuous variables, respectively.
2.5.2. Comparison of serum CRP levels between GAD cases and non-
cases
Values of serum CRP level were not normally distributed.
Therefore, we used median and interquartile range (IQR) for
descriptive results. Independent sample KruskaleWallis test was
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2.5.3. Association between serum CRP and GAD
Binary logistic regression was used to calculate odds ratio (OR)
and 95% conﬁdence internal (CI) for GAD for participants in the
middle and top thirds of CRP distribution, compared with those in
the bottom third. The use of logistic regression was appropriate
because GAD is a binary variable. Linearity of association was
examined by inspection of OR across the thirds of CRP. Regression
models were controlled for sex, age at the time of assessment of
GAD, BMI at the time of assessment of CRP, ethnicity, father's social
class, maternal highest educational level, maternal age at delivery,
and family history of chronic inﬂammatory conditions.
2.5.4. Effect of depression and infection
Effect of depression on the CRP-GAD association was examined
by excluding GAD cases with comorbid depression. Serum CRP
levels increase sharply during infection. Because we were inter-
ested in the association between GAD and CRP in healthy in-
dividuals, we re-ran the analyses after excluding individuals with
serum CRP levels >10 mg/L as such levels are highly suggestive of a
current infection (Copeland et al., 2012).
2.5.5. Imputation for missing CRP data
We employed a fully conditional speciﬁcation using themultiple
imputation by Markov chain Monte-Carlo algorithm in SPSS to
predict missing CRP data across 25 imputed datasets (Muller et al.,
2004). Each imputation model included 45 variables including past
and current anthropometric measures, cardiometabolic and other
blood biomarkers, socio-demographic indicators, and psychiatric
measurements to predict missing CRP data (full list available on
request). The association between CRP and GAD was analysed after
imputation across 25 imputed datasets.
3. Results
3.1. Baseline characteristics
Out of total 5365 participates assessed at age 16 years, 40 met
DSM-IV criteria for a diagnosis of GAD; 0.74% (95% CI, 0.55e1.02).
About 90% of GAD cases were female (Table 1).
3.2. Serum CRP levels in GAD cases and non-cases at age 16 years
Data on both serum CRP and GAD were available on 3392 in-
dividuals; this analytic sample included 26 cases of GAD (65% of all
cases of GAD at age 16 years). Median values of serum CRP were
signiﬁcantly higher in the GAD group compared with the rest of the
cohort (Fig. 1).
3.3. Odds ratio for GAD at 16 years
Fig. 2 presents proportion of GAD cases at age 16 years by thirds
of CRP. Individuals in the top third of CRP distribution were nearly
ﬁve times more likely to have a diagnosis of GAD compared with
those in the bottom third, which was signiﬁcant after adjusting for
potential confounders. The association between CRP and GAD at
age 16 years was consistent with a linear dose-response relation-
ship (Table 2).
3.4. Effect of comorbid depression
Out of 26 cases of GAD included in analyses, eight had comorbid
depression (30.77%). Median (IQR) of CRP values was not signiﬁ-
cantly different between GAD cases with and without comorbiddepression: 0.69 mg/L (0.25e1.72) and 1.04 mg/L (0.30e3.48),
respectively. Out of 18 GAD cases without comorbid depression, ten
were in the top third of CRP distribution while seven were in the
middle and one in the bottom third. These results clearly suggest
that observed associations between CRP and GAD are primarily due
to higher levels of CRP in GAD cases rather than an artefact of co-
morbid depression.
3.5. Results after excluding concurrent infection
In total, 60 participants had serum CRP levels >10mg/L, which is
suggestive of a current infection. We re-ran the regression analyses
reported in Table 2 after excluding these individuals (N ¼ 3332,
including 25 cases of GAD). All effect estimates remained virtually
unchanged (see online supplementary Table 1).
3.6. Results after imputation of missing CRP data
The pattern of results remained similar, i.e. higher CRP levels
were associated with increased risk of GAD. Out of total 40 GAD
cases, 20 (0.96%) were in the top third of CRP distribution, 12
(0.82%) were in the middle, and 8 (0.44%) in the bottom third. This
equated to a two-fold increased risk of GAD for participants in the
top compared with the bottom third of CRP distribution, although
the associations fell short of conventional statistical signiﬁcance
(see online supplementary Table 2).
4. Discussion
The ﬁndings suggest an association between higher serum CRP
levels at age 16 years and DSM-IV GAD in the general population-
based ALSPAC birth cohort, which is independent of a number of
potential confounders including sex, body mass, socio-economic
status and family history of inﬂammatory conditions. Sensitivity
analysis after excluding participants with a suspected infection
around CRP assay did not alter the results. Comparison between
cases of GAD with and without comorbid depression showed the
association was not driven by higher levels of CRP in cases with
comorbid depression. The use of a general population birth cohort,
robust assessment of outcome based on DSM-IV criteria, and ex-
amination of a number of important confounders are some of the
strengths of this study. To our knowledge this is one of the ﬁrst
general population-based studies to report an association between
GAD in adolescence and a circulating inﬂammatory biomarker.
General population-based studies of inﬂammatory markers and
anxiety disorder are scarce. However, the ﬁndings are consistent
with previous studies reporting an association between symptoms
of anxiety and higher serum levels of CRP (Liukkonen et al., 2011;
Pitsavos et al., 2006; Bullmore and Lynall, 2014; Danese et al.,
2008; Laan et al., 2007; Bankier et al., 2009; Gegenava et al.,
2011). One study based on 31 year follow up of the 1966 North-
ern Finland birth cohort reported an association between anxiety
symptoms and serum CRP in men (Liukkonen et al., 2011). Another
study based on a general population sample of healthy adults re-
ported associations between several inﬂammatory markers
including CRP and anxiety symptoms in both genders (Pitsavos
et al., 2006). However, a third population-based study did not
ﬁnd an association between inﬂammatory markers and anxiety
symptoms (Baune et al., 2012), which could be due to sample
characteristics as it focused exclusively on older adults aged be-
tween 70 and 90 years. With regards to GAD speciﬁcally, one study
reported an association between GAD and CRP, which was based on
120 stable coronary heart disease outpatient attendees (Bankier
et al., 2008). While individuals with chronic physical conditions
may not be representative of people with anxiety disorders in
Table 1
Baseline characteristics of DSM-IV Generalised Anxiety Disorder (GAD) cases and non-cases at age 16 years in the ALSPAC cohort.
Characteristics GAD No GAD c2; p-value
Number 40 5325 e
Age in years, mean (SD) 15.56 (0.24) 15.53 (0.31) 0.603; 0.54a
BMI, mean (SD) 22.55 (3.52) 21.40 (3.63) 2.158; 0.03a
Female (%) 90 52.3 22.63; <0.0001
British White ethnicity (%) 91.7 98.1 23.68; 0.003
Father's social class (%) 3.24; 0.77
I 5.9 14.0
II 44.1 37.3
III non manual 8.8 12.4
III manual 32.4 26.3
IV 5.9 8.0
V 2.9 2.0
Maternal highest education (%) 3.47; 0.48
Secondary school 16.7 11.2
Vocational 5.6 7.8
O level 41.7 34.7
A Level 16.7 28.4
Degree 19.4 17.9
Maternal age at delivery (%) 15.13; 0.01
<20 2.6 1.7
20e24 30.8 12.9
25e29 43.6 38.7
30e34 20.5 33.9
35e39 2.6 11.3
>40 0 1.5
History of arthritis in mothers (%) 8.1 3.4 2.37; 0.12
History of rheumatism in mothers (%) 5.4 3.9 0.21; 0.65
History of arthritis in maternal grandparents (%) 10.8 30.9 7.18; 0.06
History of rheumatism in maternal grandparents (%) 16.2 19.5 1.26; 0.73
a Independent sample t-test statistic and p-value.
P=0.005
GAD (n=26)
CRP Level, Median= 0.91 
mg/L (IQR= 0.28-2.56)
No GAD (n=3366)
CRP Level, Median= 0.39 
mg/L (IQR= 0.22-0.90)
Fig. 1. Serum CRP levels (mg/L) in DSM-IV GAD cases and non-cases at age 16 years in
the ALSPAC cohort.
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Fig. 2. DSM-IV GAD at age 16 years by tertiles of CRP levels in the ALSPAC cohort.
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study. We found only one general population-based study on this
topic but it did not ﬁnd an association between GAD and CRP
(measured in dried blood spots) (Copeland et al., 2012). The
discrepant results might be attributed to study methodology. There
is evidence that CRP levels in dried blood spots decline over time
making it more difﬁcult to detect (Brindle et al., 2010).
Limitations of the current study includes relatively small num-
ber of GAD cases, which led to reduced statistical power as reﬂected
by large conﬁdence interval around effect estimates both in the
observed and imputed datasets. Studies with a larger number ofGAD cases are required. However, the prevalence of GAD during
past six months diagnosed according to DSM-IV criteria at 16 years
in the ALSPAC sample was 0.74%, which is similar to other general
population-based studies of similar age groups. One year preva-
lence of DSM-IV GAD was reported to be 0.3% in a study of 3042
children aged 8e15 years from the USA (Laan et al., 2010). Ac-
cording to a national survey, the prevalence of GAD deﬁned
Table 2
Odds ratio for DSM-IV GAD for serum CRP levels at age 16 years in the ALSPAC cohort.
Groupsa N GAD cases, n (%) Odds ratio (95% conﬁdence interval)
Unadjusted Adjusted for age, sex, BMI Adjusted for age, sex,
BMI, social class,
ethnicity
Adjusted for age, sex,
BMI, social class, ethnicity,
maternal education and
age at delivery
Additional adjustment for
family history of chronic
inﬂammatory conditionsb
Bottom third 1093 3 (0.3) 1.00 1.00 1.00 1.00 1.00
Middle third 1151 9 (0.8) 2.86 (0.77e10.60) 2.92 (0.78e10.92) 2.39 (0.60e9.47) 2.42 (0.60e9.75) 2.25 (0.55e9.20)
Top third 1148 14 (1.2) 4.48 (1.28e15.65) 4.67 (1.28e16.97) 4.69 (1.25e17.51) 4.88 (1.28e18.54) 5.06 (1.31e19.59)
Linear trend 3392 26 (0.76) 1.95 (1.14e3.32) 1.99 (1.14e3.47) 2.11 (1.16e3.85) 2.16 (1.17e3.98) 2.25 (1.19e4.23)
a The group at the bottom third of CRP distribution was used as reference category. Cut off values for the top and bottom thirds of CRP distribution in the entire sample were
0.64 and 0.26 mg/L, respectively.
b Includes history of arthritis and rheumatism in mother and maternal grandparents.
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the UK (Statistics OfN, 1999). Another issue is missing data. Out of
5365 individuals assessed for GAD at age 16 years, about a third had
no data on CRP. However, the proportion of GAD cases was similar
between the analytic sample and the group with missing CRP data.
No signiﬁcant differences between these groups were observed in
terms of distribution of potential confounders such as age, sex,
social class and ethnicity. Thus, any signiﬁcant bias arising from
missing data is unlikely. Data regarding inﬂammatory markers
included only serum CRP. In the future, examination of a range of
inﬂammatory markers, such as IL-6 and other cytokines would be
useful. CRP levels were appropriate for the age of the subjects.
GAD is characterised by persistent, excessive and uncontrollable
worry (APA, 1995). A cross-sectional association between levels of
CRP and GAD might reﬂect increased levels of stress perceived by
individuals with this illness. Both physical and psychological stress
can provoke transient increase in proinﬂammatory cytokines. Rats
exposed to electric foot-shock, physical restraint, or a conditioned
aversive stimulus have increased levels of plasma IL-6 (Zhou et al.,
1993). Similarly, in humans acute or chronic stress is associated
with increase in levels of circulating proinﬂammatory cytokines
(Maes et al., 1998; Kiecolt-Glaser et al., 2003). The current ﬁndings
are consistent with previous studies reporting increased CRP and
other inﬂammatory markers in depression and post-traumatic
stress disorder (von Kanel et al., 2007; Howren et al., 2009;
Haapakoski et al., 2015). Recently a population-based longitudinal
study has reported a longitudinal association between serum IL-6
in childhood and risks of depression and psychosis in young adult
life (Khandaker et al., 2014); these ﬁndings along with other lon-
gitudinal studies (Gimeno et al., 2009;Wium-Andersen et al., 2014)
indicate a potentially causal role of inﬂammation in depression
(Khandaker et al., 2014; Gimeno et al., 2009) and schizophrenia
(Khandaker et al., 2015; Khandaker and Dantzer, 2015). In future
longitudinal studies of inﬂammatory markers and GAD are needed
for a clearer understanding of the direction of this association.
The relationship between systemic inﬂammation, mood and
anxiety is complex (Messay et al., 2012). There is evidence that
prior stress exposure have a priming effect on inﬂammatory cyto-
kine response, as reﬂected by a larger or more rapid induction of
these molecules following immune activation (Johnson et al.,
2002). Thus, increased inﬂammatory markers in GAD might
reﬂect previous exposure to stressful events, a known risk factor
for anxiety disorders (Heim and Nemeroff, 2001). In the future,
studies should include measures of current psychological stress,
past trauma and maltreatment as well as stress-related biomarkers
such as cortisol in order to elucidate the effect of stress on the as-
sociation between inﬂammation and anxiety.
Animal studies provide useful insights into potential mecha-
nisms underlying the association between systemic inﬂammation
and anxiety. Peripheral cytokines can communicate with the brainin a number of ways to leading to neuropsychiatric symptoms
relevant for anxiety, mood and psychotic disorders; for reviews see
(Dantzer et al., 2008; Khandaker and Dantzer, 2015; Stolk et al.,
2007; D'Mello and Swain, 2014; Quan and Banks, 2007). Possible
routes for peripheral immune to brain communication include (i)
leaky regions in the bloodebrain barrier, such as circumventricular
organs, (ii) active transport via soluble transport molecules, (iii)
activation of endothelial cells and macrophages in the lining of
cerebral vasculature (which then produce cytokines and facilitate
transmigration of inﬂammatory cells in the brain), and (iv) retro-
grade axonal transport through peripheral afferent nerve ﬁbres
(e.g. the vagus nerve). Once the cytokine signal reaches the brain,
the CNS cytokine network (made up of neurons and glial cells) not
only produce cytokines and cytokine receptors within brain tissue
but also amplify the signal (Dantzer, 2004). This, in turn, leads to a
number of changes relevant for neuropsychiatric symptoms seen in
anxiety and depression. The changes include (i) increased meta-
bolism and reuptake of serotonin and other mood-relevant neu-
rotransmitters, (ii) stimulation of the hypothalamic-pituitary-
adrenal axis and release of corticotrophin releasing hormone in
hypothalamus and amygdala, (iii) increasing oxidative stress and
thus reducing synaptic plasticity (Dantzer et al., 2008; Miller et al.,
2009). Crucial evidence linking proinﬂammatory cytokines, anxiety
and depression comes from recent animal studies. Rossi and col-
leagues reported that administration of the cytokine IL-1b induces
anxiety in mice, and anxiety inducing effects of social defeat could
be blocked by ICV administration of an IL-1b receptor antagonist
immediately after stress exposure. Similarly, in mice inhibiting IL-6
by monoclonal antibody injection prevents stress-induced
depression-like behaviour (Hodes et al., 2014). The results suggest
that inﬂammatory cytokines may be important mediators of the
link between stress and anxiety.
In summary, we report a general population-based study of an
association between higher serum levels of CRP and clinical diag-
nosis of GAD according to DSM-IV criteria in adolescence. These
ﬁndings need replication. Current epidemiological evidence
regarding anxiety and inﬂammatory markers is limited, although
population-based studies indicate an association between higher
serum CRP levels and symptoms of anxiety. Longitudinal studies
with measures of inﬂammation, subsequent diagnosis of anxiety
taking into account current and past exposure to psychological
stress are required to further elucidate the association between
anxiety and inﬂammation.
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